MarketPulse

biologic therapies

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Myasthenia Gravis Market Poised to Balloon to $16B by 2036 on Biotech Boom

Myasthenia gravis market projected to grow from $6B (2025) to $16B (2036), fueled by diagnostic improvements, rising prevalence, and novel biologic therapies from companies like argenx and UCB.
JNJARGXNVSAZNREGN+4clinical trialsrare disease
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

SLE Drug Market to Nearly Triple to $5.9B by 2034 as New Therapies Challenge Generics

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.
BMYCELGrABBVNVSRHHBY+3market forecastbiosimilars
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

SLE Drug Race Heats Up: 120+ Pharma Giants Develop 140+ Pipeline Therapies

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.
JNJABBVNVSRHHBYAZN+3FDA approvalclinical trials